Moody Aldrich Partners’s Albany Molecular Research Inc AMRI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q2
– Sell
-21,930
Closed -$308K – 104
2017
Q1
$308K Sell
21,930
-43,117
-66% -$706K 0.53% 78
2016
Q4
$1.22M Sell
65,047
-74,730
-53% -$1.27M 0.79% 63
2016
Q3
$2.31M Buy
139,777
+14,520
+12% +$215K 1.61% 14
2016
Q2
$1.68M Buy
125,257
+78,752
+169% +$1.15M 1.39% 22
2016
Q1
$711K Buy
+46,505
New +$729K 1.5% 22

Other funds holding AMRI

Moody Aldrich Partners's AMRI Position: Q2 2017 in Review

Moody Aldrich Partners sold out of Albany Molecular Research Inc (AMRI) in Q2 2017, closing a stake of 21,930 shares — an estimated $308K sold.

Moody Aldrich Partners first reported a position in AMRI in Q1 2016 and held it in 5 quarters. The position peaked at $2.31M in Q3 2016. 136 funds tracked by Wall St. Rank hold AMRI as of Q2 2017.

  • Moody Aldrich Partners reported no remaining Albany Molecular Research Inc position as of Q2 2017 after selling out during the quarter.
  • Moody Aldrich Partners sold 21,930 Albany Molecular Research Inc shares in Q2 2017, an estimated $308K.
  • Moody Aldrich Partners first reported a position in Albany Molecular Research Inc in Q1 2016 and held it in 5 quarters.
  • Moody Aldrich Partners's Albany Molecular Research Inc position peaked at $2.31M in Q3 2016.
  • 136 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q2 2017.

Based on Moody Aldrich Partners's 13F filing for Q2 2017, filed 28 Jul 2017.